Hjem › Burkitts lymfom › Illinois
Burkitts lymfom kliniske forsøg i Illinois
14 studier for Burkitts lymfom søger deltagere på steder i Illinois.
Byer i Illinois
Officiel studietekst (engelsk)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 4 flere
RekruttererFase 2
366 Days – 46 Years · Alle køn · Opdateret 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
- og 7 flere
RekruttererFase 3
Alder 18 til 39 · Alle køn · Opdateret 2. okt. 2026 · NCT03150693Blinatumomab Consolidation in Real World
- Northwestern University, Chicago
- The University of Chicago, Chicago
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07117136Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwestern University, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 9 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Children's Hospital-Oak Lawn, Oak Lawn
- og 3 flere
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 2 flere
RekruttererFase 2
Alder 1 til 30 · Alle køn · Opdateret 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lurie Children's Hospital-Chicago, Chicago
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- og 5 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
RekruttererFase 2
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Chicago
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT06137118Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Chicago
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 13. jul. 2026 · NCT07109219Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- University of Chicago Comprehensive Cancer Center, Chicago
RekruttererFase 2
Alder 18 til 54 · Alle køn · Opdateret 17. mar. 2026 · NCT06918431ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- University of Chicago Comprehensive Cancer Center, Chicago
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 4. nov. 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of Chicago, Chicago
RekruttererFase 1/2
Alder 15 til 50 · Alle køn · Opdateret 9. sep. 2025 · NCT04150497Study of Nutrition and Exercise in Adults Hospitalized for Treatment of Acute Lymphoblastic Leukemia (ALL)
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Rekrutterer
Alder 18 til 50 · Alle køn · Opdateret 19. jun. 2025 · NCT06785324Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.